from upper neck pain and/or headache due to bilateral 3rd occipital nerve involvement, excluding other local cervical spine pathologies was confirmed by MRI and previously failed conservative treatment for at least three months prior to enrolment. Sixty adult patients were randomly assigned to one of the two studied groups Group 1 (RF; n = 30), received bilateral Third occipital nerve Radiofrequency under fluoroscopic guidance or Group 2 (control group, n = 30), received oral prednisolone 10 mg/day. The two groups were then followed-up with neck disability index (NDI), nocturnal neck pain VAS score and headache score every two weeks for three months. Sleep disturbance, sleep disability index were reassessed six months post intervention. Post interventional assessment was done by pain physician who were kept blind to the grouping process. 

Results: Neck disability index (1 try outcome), Nocturnal pain VAS, and severity of headache showed significant differences during the whole post-interventional study period. The patients in RF group demonstrated significant improvement of pain in comparison to baseline value over the whole six months with p-value < 0.001 as regard to the fore-mentioned three parameters. On the other aspect, the control group patients showed significant improvement in comparison to its baseline value after the 2nd, 12th and 24th weeks only as follows: (0.001, 0.003, 0.003 for the NDI) (p values of 0.02,0.01, 0.01 for the nocturnal pain VAS), (0.001, 0.009, 0.005 for the headache VAS severity.

Conclusion: Radiofrequency of 3rd occipital nerve is effective in treatment of refractory cervicogenic headache in RA.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2020-eular.241

THU0454 SOMATIC SYMPTOMS IN FIBROMYALGIA AND THEIR CORRELATION WITH DRUG TREATMENT

M. Antivalle1, M. Agosti2, A. Batticciotto3, S. Costi3, V. Giorgi1, P. Sarzi Puttini1.
1L. Sacco University Hospital, Rheumatology, Milano, Italy; 2L. Sacco University Hospital, Rheumatology, Milano, Italy; 3Ospedale di Circolo e Fondazione Macchi, Rheumatology, Varese, Italy

Background: Drug treatment in fibromyalgia (FM) is often disappointingly ineffective, and there are currently very few data to support therapeutic choices towards a personalized medicine approach.

Objectives: To evaluate the prevalence of selected somatic symptoms in FM, and to study their relationship with drug treatments.

Methods: The study population consisted of 526 patients (471 F 55 M, mean age 47.3±11.33 yrs) affected by FM not associated with other rheumatic diseases. All patients were required to compile a questionnaire reporting the presence of 42 somatic symptoms -as suggested (1) – in the last 7 days. Drug usage was assessed by interview.

Results: On average, patients reported the presence of 17.04±6.68 symptoms (range 4-35), with ample variations in the prevalence of different symptoms (Fig. 1), ranging from over 95% (fatigue and muscle pain) to less than 10%, siendo worst reported by only 2 patients (0.4%). 31.1% of patients were not taking any drug for their FM. The most frequently used drugs were analgesics (ANA, 41.7%) followed by benzodiazepines (BD, 29.1%), SSRIs (16%), gabapentinoids (GABA, 14.4%), and NSRI (14.3%) (Fig. 2). Different drugs were associated with a different spectrum of somatic symptoms: as compared to non users, BD users reported a significantly higher (p<0.05 by chi-square test) prevalence of irritable bowel (65.4% vs 52.3%), fatigue (98.7% vs 94.9%), thinking difficulties (78.4% vs 68.5%), muscle weakness (94.1% vs 81.7%), abdominal pain (55.6% vs 43.9%), insomnia (73.9% vs 56.6%), depression (63.4 % vs 37.2%), constipation (60.1% vs 42.9%), pain in upper abdomen (50.3% vs 40.2%), nausea (53.6% vs 38.3%), nervousness (71.9% vs 61.5%), chest pain (49.9 vs 37.7), blurred vision (65.4% vs 53.6), dry mouth (72.5% vs 52.3%), itching (56.2% vs 44.5%), vomiting (13.7% vs 7.8%), taste change (22.2% vs 12.7%), dry eyes (55.6% vs 41.0%), breath shortness (56.9% vs 47.7%), appetite loss (33.3% vs 19.7%), painful urination (15.0% vs 8.4%), and bladder spasms (18.3% vs 8.6%). NSRI users reported a significantly higher prevalence of thinking difficulties, constipation, blurred vision, dry mouth, wheezing, dry eyes, easy bruising. Among GABA users, there was a higher prevalence of thinking difficulties, numbness, insomnia, constipation, nausea, dry mouth, dry eyes, appetite loss, sun sensitivity, easy bruising, and bladder spasms. In no cases a higher prevalence of symptoms was recorded in drug non users vs users. 

Conclusion: The usage of different drugs in FM is associated with different somatic symptoms. The higher prevalence of symptoms in drug users as compared to non users raises serious questions concerning the opportunity or the appropriateness of drug selection in FM.

References:

THU0455 DIFFERENCES IN PSYCHIATRIC COMORBIDITIES AND LIFE ADVERSITIES BETWEEN PATIENTS WITH RHEUMATOID ARTHRITIS ASSOCIATED WITH FIBROMYALGIA AND PATIENTS WITH PRIMARY FIBROMYALGIA

F. Atzeni1, M. Cirillo1, I. F. Masala1, E. Gerritana1, D. Sangari1, G. Miceli1, P. Sarzi-Puttini1, A. Alciati1,1 Rheumatology Unit, University of Messina, Messina, Italy; 2Trauma and Orthopedic Unit, Santissima Trinità Hospital, Cagliari, Italy; 3Department of Rheumatology, University Hospital ASST Fatebenefratelli Sacco, Milan, Italy; 4Department of Clinical Neurosciences, Hermanas Hospitalarias, Villa S. Benedetto Menni Hospital, Albese (Como), Italy 5Humanitas Clinical and Research Center, IRCCS, Rozzano, Italy, Como, Italy

Background: Patients with rheumatic arthritis (RA) continue to report significant pain despite apparent disease control by immunosuppressive drugs (1), leading to the hypothesis that central sensitisation (CS) plays a role in the chronic muscular-skeletal pain defining fibromyalgia (FM).

Objectives: The aim of our study was to evaluate the differences in psychiatric comorbidities and life adversities between patients with RA+FM and patients with primary FM (PFM).

Methods: In an observational cross-sectional study patients with PFM and AR+FM were consecutively recruited. The inclusion criteria were an age of 18-70 years; a diagnosis of RA according to the 2010 ACR classification criteria and FM according to the 1990 ACR criteria and 2016 ACR criteria. Lifetime diagnoses of major depression disorder (MDD), panic disorder (PD) and post-traumatic stress disorder (PTSD), three of the most frequently described psychiatric disorders among FM patients, were made with the Structured Clinical Interview for DSM-5. Depressive symptoms were measured using the Zung Self-rating Depression Scale (ZSDS). Childhood trauma was measured using the short form of the Childhood Trauma Questionnaire (CTQ) and stressful events were assessed....

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2020-eular.6427
using the Paykel's Interview for Recent Life Events. Pain was assessed using a visual analogue scale (VAS). The Fibromyalgia Impact Questionnaire (FIQ) was also used.

**Results:** Seventy-seven patients were originally screened, but seven were excluded because of current depressive episode or having a ZSDS of ≥60 or categorized as minimizers of childhood maltreatment at CTQ. The final analysis therefore involved 70 patients, all Caucasians: 30 with PFM and 40 with AR+FM. All patients with PFM and 38 (85%) of the 40 with AR+FM were treated for FM symptoms (antidepressants, pregabalin). The lifetime rates of MDD were significantly higher in PFM vs AR+FM (76.7% and 40% respectively, p = 0.003), as well as the rates of PD (50% and 15% respectively, p < 0.003), whereas there was no difference in PTSD rates. The PFM patients reported significantly higher levels of physical (p = 0.020) and sexual abuse (p = 0.011) and physical neglect (p < 0.001), whereas there was no between-group difference in the levels of emotional abuse (p = 0.912) and neglect (p = 0.542); consistently, the proportion of sexually abused (p = 0.005) or physically neglected patients was also higher in the PFM group (p = 0.023). The rates of emotional neglect were high in both groups, without any significant difference between them. The vast majority of AR+FM patients (90%) said that only event occurring in the year preceding the onset of FM was RA, whereas the PFM patients mainly reported nonphysical events (36%), particularly the ending of a relationship, or working or financial problems) or no event at all (40%), (p = 0.001). Binary logistic regression used to identify the factors predicting association of PFM/AR+FM status, showed an association with lifetime major depression, life events preceding the development of FM, and BMI (p = 0.05 at all).

**Conclusion:** PFM and SFM differ in psychiatric co-morbidities and environmental adversities, suggesting that the putative common pathogenetic condition of CS may develop through different pathways.

**References:**

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2020-eular.3894

---

**THU0456**

THE “JOINT CRITERIA” FOR FIBROMYALGIA DIAGNOSIS IN RHEUMATOID ARTHRITIS PATIENTS: RELIABILITY COMPARED TO THE 2010 ACR CLASSIFICATION CRITERIA FOR FIBROMYALGIA

L. J. Ghi1, A. Barca1, A. D. Bilouš2, I. Cosma3, M. M. Tamas1,1,1, I. Filipescu1,1, I. Felea1, L. Damian1, L. Muntean1,3, S. P. Simon1,3, S. Rednic1,3,1,1,1,Jului Hateganu1University of Medicine and Pharmacy, Rheumatology; Cluj-Napoca, Romania; 2Rehabilitation Clinical Hospital, Cluj-Napoca, Romania; 3Emergency Clinical County Hospital Cluj, Rheumatology, Cluj-Napoca, Romania

**Background:** A significant proportion of rheumatoid arthritis (RA) patients have concomitant fibromyalgia (FM) (1). Associated FM diagnosis in RA patients can determine worse treatment outcomes compared to patients without FM (1). A difference between tender joint count (TJC) and swollen joint count (SJC) ≥7, also named the “joint criteria” was proposed as being diagnostic for FM in patients with RA. The “joint criteria” were validated against the 1990 ACR Classification Criteria for FM and are easy to apply to patients with RA (2). Since then, the 2010 ACR Classification criteria for FM, which include somatic symptoms besides pain sensitivity, were developed and validated.

**Objectives:** To aimed to determine the reliability of the joint criteria for fibromyalgia in RA compared to the ACR 2010 Classification Criteria for FM and to compare RA patients diagnosed with FM (FRA) to those without FM in terms of clinical variables.

**Methods:** We performed a cross-sectional study on RA patients who presented in our department during a 3 months period. Tender joint count (TJC), swollen joint count (SJC), patient global assessment of disease activity (PGA) were determined. DAS28 scores were calculated using CRP We applied the 2010 ACR Classification Criteria and the joint criteria for FM diagnosis. Kappa agreement coefficient was used to determine the reliability of the joint criteria against the 2010 ACR Classification Criteria for FM in patients with RA. Differences between groups were assessed using Mann-Whitney U test for numerical data or Chi square test for ordinal data.

**Results:** We included 100 consecutive RA patients, 84% female, with a mean age of 57.3(12) years and mean disease duration of 14(9) years. Twenty-four patients (24%) had associated FM according to the ACR 2010 Classification Criteria and 22 (22%) patients satisfied the joint criteria for associated FM. The level of agreement between the joint criteria and the ACR 2010 classification criteria for FM was kappá=0.86, p< 0.001, with a sensitivity of 70% and a specificity of 93%. FRA patients had similar demographic and disease characteristics compared to RA patients. Patients with FRA according to the joint criteria had significantly higher PGA, DAS28, and HAQ scores, but similar CRP values and SJC compared to RA patients (Table 1).

<table>
<thead>
<tr>
<th>Variable</th>
<th>FRA n=22</th>
<th>RA n=78</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>60 (10.7)</td>
<td>59 (12.2)</td>
<td>0.093</td>
</tr>
<tr>
<td>Disease Duration (years)</td>
<td>13.3 (13)</td>
<td>12.2 (7.5)</td>
<td>0.589</td>
</tr>
<tr>
<td>ACPA seropositivity(%)</td>
<td>69</td>
<td>55</td>
<td>0.1</td>
</tr>
<tr>
<td>SJC</td>
<td>2(4)</td>
<td>2(4)</td>
<td>0.7</td>
</tr>
<tr>
<td>CRP (g/dl)</td>
<td>12.8(14.2)</td>
<td>8.1(13.7)</td>
<td>0.06</td>
</tr>
<tr>
<td>DAS28CRP</td>
<td>4 (1.7)</td>
<td>3.5 (1.2)</td>
<td>0.009</td>
</tr>
<tr>
<td>HAQ</td>
<td>1.75 (0.5)</td>
<td>1 (0.7)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>PGA (mm)</td>
<td>70(11)</td>
<td>44(23)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Data are expressed as mean (SD) or median (IQR)

**Conclusion:** The joint criteria are diagnostic for FM in RA patients with moderate reliability compared to the ACR 2010 Classification criteria. When diagnosed with the joint criteria, FRA patients have higher disease activity scores despite having similar clinical and laboratory inflammatory markers compared to RA patients.

**References:**

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2020-eular.3285

---

**THU0457**

LONGITUDINAL ASSOCIATION OF SEDENTARY TIME AND PHYSICAL ACTIVITY WITH SLEEP QUALITY IN WOMEN WITH FIBROMYALGIA: THE AL-ANDALUS PROJECT

M. Borges Coste1, P. Acosta-Manzano2, B. Gavilán Carrera3, F. Estévez-López2, V. A. Aparicio1, V. Segura-Jiménez4, M. Delgado-Fernández5,1

1University of Granada, Faculty of Sport Sciences, Department of Physical Education and Sport, Granada, Spain; 2University of Granada, Faculty of Sport Sciences, Department of Physical Education and Sport, Granada, Spain; 3Erasmus MC University Medical Center, Department of Child and Adolescent Psychiatry/Psychology, Rotterdam, Netherlands; 4University of Granada, Faculty of Pharmacy, Department of Physiology, Granada, Spain; 5University of Cádiz, Faculty of Physical Education, Department of Physical Education, Cádiz, Spain

**Background:** Sleep disturbances are common in fibromyalgia, and influences quality of life. Recent literature has suggested that non-pharmacological treatments (e.g., physical exercise and cognitive behavioural therapy) may help to improve sleep quality (SQ) and the management of fibromyalgia. In this regard, sedentary time (ST) and physical activity (PA) intensity levels could play a role on SQ in this population. Therefore, evidence is scarce and mainly based on cross-sectional data.

**Objectives:** This study aimed to examine the longitudinal associations (2- and 5-year follow-up) of ST and PA intensity levels with SQ in women with fibromyalgia.

**Methods:** In this prospective cohort study, women diagnosed with fibromyalgia (age: 51±5 years) with complete data were included at baseline (n=409), at 2-year follow-up (n=214) and at 5-year follow-up (n=218). Sedentary time and PA intensity levels (light and moderate-to-vigorous [MVPA]) were assessed using triaxial accelerometers worn for consecutive 7 days. The percentage of time spent in different behaviours was calculated (e.g., (ST/accelerometer wear time) × 100). The SQ global score was calculated as a sum of all components (score

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2020-eular.3285